Please assess the completion status of the following clinical trial:

Trial Title: Study of TLK199 HCl Liposomes for Injection in Myelodysplastic Syndrome

Study Design Characteristics:
- Allocation: NON_RANDOMIZED
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE1/PHASE2
- Number of Arms: None

Eligibility Criteria:
Inclusion Criteria:~* Histologically or cytologically confirmed diagnosis of MDS~* Adequate liver and kidney function~* Ineligible for, or refusing, allogeneic bone marrow transplant~* At least 18 years of age~* Discontinuation of growth factors (e.g., G- CSF) at least 2 weeks prior to study entry~Exclusion Criteria:~* Failure to recover from any prior surgery, or any major surgery within 4 weeks of study entry~* Pregnant or lactating women~* History of allergy to eggs~* Other investigational drugs within 14 days of study entry~* Chemotherapy, radiotherapy or immunotherapy within 14 days of study entry~* Concomitant steroids or hormones for the treatment of neoplasms

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Based on this trial design, predict the completion outcome and termination type (if applicable).